

ID No.	K2006
Project Title	Establishment of drug testing system for a precision medicine in cholangiocarcinoma
Principal Investigator	Watcharin Loilome (Associate Prof., Kohn Kaen Univ.(KKU))
Project Members IMSUT Host Researcher Members	<p>Yoshinori Murakami (Prof., IMSUT)</p> <p>Narong Khuntikeo (Associate Prof., KKU)</p> <p>Attapol Titapun (Surgeon, KKU)</p> <p>Hasaya Dokduang (Research Associate, KKU)</p> <p>Poramate Klanrit (Postdoc., KKU)</p> <p>Jutarop Petcharaburanin (Postdoc., KKU)</p> <p>Daisuke Matsubara (Associate Prof., Jichi Medical Univ.)</p> <p>Motoi Oba (Research Associate, IMSUT)</p> <p>Yutaka Kasai (Research Associate, IMSUT)</p> <p>Takeshi Ito (Assistant Prof., IMSUT)</p>
Report	<p>In the present collaboration, we are challenging multi-omics and drug sensitivity analyses of patient-derived CCA tissues from Thailand and Japan by several new techniques in molecular pathology, including histo-culture drug response assay (HDRA), patient-derived xenografts (PDX), and patient-derived organoids (PDO). Extensive screening systems of cell adhesion molecules, which was established by IMSUT team, is going to be used to identify key molecules in malignant progression of CCA, including those involved in cancer-stromal cells interactions, such as immune cells and vascular endothelial cells, in CCA. In 2019 and 2020, we preliminary generated HDRA, PDX and PDO in CCA by exchanging the information through E-mail discussion and Zoom discussion, instead of direct collaboration by visiting scientists from KKU to IMSUT, which could not be achieved due to COVID-19 pandemic. We are going to hold a Zoom meeting by all members of this project in Thailand and Japan in an appropriate day from January to March, 2021.</p>